



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Steven B. Landau  
Application No.: 10/757,364 Group Art Unit: Unknown  
Filed: January 13, 2004 Examiner: Unknown  
Confirmation No.: Unknown  
Title: METHOD OF TREATING FUNCTIONAL BOWEL DISORDERS

| CERTIFICATE OF MAILING OR TRANSMISSION  |                |
|---|----------------|
| I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on: |                |
| 2-11-04   | Denise Carideo |
| Date  | Signature      |
| Denise Carideo  |                |
| Typed or printed name of person signing certificate   |                |

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.129(a), or  
(First/Second submission after Final Rejection)
- ☒ under 37 CFR 1.97(b), or  
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
- ☐ under 37 CFR 1.97(c) together with either:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, or
- ☐ a \$180.00 fee under 37 CFR 1.17(p), or  
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, and
- ☐ a \$180.00 fee under 37 CFR 1.17(p), or  
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
- ☐ under 37 CFR 1.97(i):  
Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.  
(Filed after payment of issue fee)



Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☒ Copies of the cited references are enclosed.
- ☒ Since this application was filed after June 30, 2003, copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
- ☐ Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
- ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- ☒ The "concise explanation" requirement (non-English references) for references AN2 and AM3 under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
- ☐ the explanation provided in the Specification.
- ☐ submission of the enclosed International Search Report.
- ☐ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
- ☒ the enclosed English language abstracts.



[X] Applicant requests that the following non-published pending applications be considered:

Examiner's  
Initials

\_\_\_\_\_ U.S. Patent Application No. 10/757,981, by Landau *et al.*, filed January 13, 2004, Docket No.: 3506.1001-002

\_\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

\_\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

\_\_\_\_\_  
Examiner

\_\_\_\_\_  
Date

[X] A copy of the above-cited application, including the current claims, is enclosed.

[ ] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Remarks

References AX4 and AY4 are copies of the British priority documents for International Application No. PCT/GB2003/002974 (WO 2004/004734 A1, published on January 15, 2004, Reference AL2). Copies of priority documents for international applications filed under the Patent Cooperation Treaty are available through WIPO upon publication of the international application pursuant to Rule 17.2(c) PCT. Copies of References AX4 and AY4 were obtained in this manner.

Method of payment:

[ ] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.

[ ] Please charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is enclosed.

[X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Pamela A. Torpey  
Pamela A. Torpey  
Registration No.: 45,736  
Telephone: (978) 341-0036  
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: February 11, 2004



PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.  
3506.1000-002APPLICATION NO.  
10/757,364INFORMATION DISCLOSURE CITATION  
IN AN APPLICATIONFIRST NAMED INVENTOR  
Steven B. LandauFILING DATE  
January 13, 2004

February 11, 2004

EXAMINER  
UnknownCONFIRMATION NO.  
UnknownGROUP  
Unknown

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS


| EXAM-<br>INER<br>INI-<br>TIAL | REF.<br>NO. | DOCUMENT NUMBER<br>Number-Kind Code (if known) | ISSUE DATE /<br>PUBLICATION DATE<br>MM-DD-YYYY | NAME OF PATENTEE OR APPLICANT<br>OF CITED DOCUMENT |
|-------------------------------|-------------|--|--|--|
|                               | AA          | 4,695,568                                      | 09-22-1987                                     | Ninomiya <i>et al.</i>                             |
|                               | AB          | 4,939,136                                      | 07-03-1990                                     | Haeck <i>et al.</i>                                |
|                               | AC          | 5,225,407                                      | 07-06-1993                                     | Oakley <i>et al.</i>                               |
|                               | AD          | 5,352,685                                      | 10-04-1994                                     | Maruyama <i>et al.</i>                             |
|                               | AE          | 5,434,174                                      | 07-18-1995                                     | Gidda <i>et al.</i>                                |
|                               | AF          | 5,438,068                                      | 08-01-1995                                     | Eeckhout <i>et al.</i>                             |
|                               | AG          | 5,470,868                                      | 11-28-1995                                     | Young  |
|                               | AH          | 5,576,317                                      | 11-19-1996                                     | Gonsalves  |
|                               | AI          | 5,663,343                                      | 09-02-1997                                     | van der Meij <i>et al.</i>                         |
|                               | AJ          | 5,945,415                                      | 08-31-1999                                     | Kato <i>et al.</i>                                 |
|                               | AK          | 5,962,494                                      | 10-05-1999                                     | Young  |
|                               | AA2         | 5,977,175                                      | 11-02-1999                                     | Lin  |
|                               | AB2         | 5,985,866                                      | 11-16-1999                                     | Müller <i>et al.</i>                               |
|                               | AC2         | 5,990,159                                      | 11-23-1999                                     | Meulemans <i>et al.</i>                            |
|                               | AD2         | 6,054,461                                      | 04-25-2000                                     | Fairbanks <i>et al.</i>                            |
|                               | AE2         | 6,117,879                                      | 09-12-2000                                     | Fairbanks <i>et al.</i>                            |
|                               | AF2         | 6,156,771                                      | 12-05-2000                                     | Rubin <i>et al.</i>                                |
|                               | AG2         | 6,235,745 B1                                   | 05-22-2001                                     | Megens   |
|                               | AH2         | 6,284,770 B1                                   | 09-04-2001                                     | Mangel <i>et al.</i>                               |
|                               | AI2         | 6,300,336 B1                                   | 10-09-2001                                     | Eeckhout <i>et al.</i>                             |
|                               | AJ2         | 6,355,647 B1                                   | 03-12-2002                                     | Steiner <i>et al.</i>                              |
|                               | AK2         | 6,384,042 B2                                   | 05-07-2002                                     | Färber <i>et al.</i>                               |
|                               | AA3         | 6,429,209 B2                                   | 08-06-2002                                     | Mangel <i>et al.</i>                               |
|                               | AB3         | 6,440,453 B1                                   | 08-27-2002                                     | Fischer <i>et al.</i>                              |
|                               | AC3         | 6,441,038 B1                                   | 08-27-2002                                     | Loder <i>et al.</i>                                |
|                               | AD3         | 6,458,795 B1                                   | 10-01-2002                                     | Bergeron, Jr.                                      |

EXAMINER

DATE CONSIDERED



PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.  
3506.1000-002APPLICATION NO.  
10/757,364FIRST NAMED INVENTOR  
Steven B. LandauFILING DATE  
January 13, 2004EXAMINER  
UnknownCONFIRMATION NO.  
UnknownGROUP  
UnknownINFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

February 11, 2004

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

| EXAM-<br>INER<br>INI-<br>TIAL | REF.<br>NO. | DOCUMENT NUMBER<br>Number-Kind Code (if known) | ISSUE DATE /<br>PUBLICATION DATE<br>MM-DD-YYYY | NAME OF PATENTEE OR APPLICANT<br>OF CITED DOCUMENT |
|-------------------------------|-------------|--|--|--|
|                               | AE3         | 6,465,458 B1                                   | 10-15-2002                                     | Wong <i>et al.</i>                                 |
|                               | AF3         | 6,566,369 B2                                   | 05-20-2003                                     | Cautreels <i>et al.</i>                            |
|                               | AG3         | 6,588,708 B1                                   | 05-06-2003                                     | Lin  |
|                               | AH3         | 2001/0020025 A1                                | 09-06-2001                                     | Megens   |
|                               | AI3         | 2001/0044450 A1                                | 11-22-2001                                     | Mangel <i>et al.</i>                               |
|                               | AJ3         | 2001/0056110 A1                                | 12-27-2001                                     | Faerber <i>et al.</i>                              |
|                               | AK3         | 2002/0002197 A1                                | 01-03-2002                                     | Mueller <i>et al.</i>                              |
|                               | AA4         | 2002/0040033 A1                                | 04-04-2002                                     | Cautreels <i>et al.</i>                            |
|                               | AB4         | 2002/0086880 A1                                | 07-04-2002                                     | Rubin <i>et al.</i>                                |
|                               | AC4         | 2002/0086881 A1                                | 07-04-2002                                     | Rubin <i>et al.</i>                                |
|                               | AD4         | 2002/0107244 A1                                | 08-08-2002                                     | Howard, Jr.  |
|                               | AE4         | 2003/0125349 A1                                | 07-03-2003                                     | Cautreels <i>et al.</i>                            |
|                               | AF4         | 2003/0203055 A1                                | 10-30-2003                                     | Rao <i>et al.</i>                                  |
|                               | AG4         | 6,593,336 B2                                   | 07-15-2003                                     | Mangel <i>et al.</i>                               |
|                               | AH4         | 2003/0036549 A1                                | 02-20-2003                                     | Mangel <i>et al.</i>                               |
|                               | AI4         | 6,211,171 B1                                   | 04-03-2001                                     | Sawynok <i>et al.</i>                              |
|                               | AJ4         | 5,530,008                                      | 06-25-1996                                     | Azcona <i>et al.</i>                               |
|                               | AK4         | 5,977,127                                      | 11-02-1999                                     | Bonnacker <i>et al.</i>                            |
|                               | AA5         | 4,845,092                                      | 07-04-1989                                     | Sanger <i>et al.</i>                               |
|                               |             |  |  |  |
|                               |             |  |  |  |
|                               |             |  |  |  |
|                               |             |  |  |  |
|                               |             |  |  |  |
|                               |             |  |  |  |

EXAMINER

DATE CONSIDERED



3506.1000-002

10/757,364

Steven B. Landau

January 13, 2004

## Unknown

Unknown

Unknown

February 11, 2004

(Use several sheets if necessary)


## FOREIGN PATENT DOCUMENTS

[illegible]

EXAMINER

DATE CONSIDERED



|  |  |                               |                                 |
|--|--|-------------------------------|---------------------------------|
| PTO-1449 REPRODUCED<br><br> INFORMATION DISCLOSURE CITATION<br>IN AN APPLICATION<br>February 11, 2004<br>(Use several sheets if necessary) | ATTORNEY DOCKET NO.<br>3506.1000-002     | APPLICATION NO.<br>10/757,364 |                                 |
|  | FIRST NAMED INVENTOR<br>Steven B. Landau |                               | FILING DATE<br>January 13, 2004 |
|  | EXAMINER<br>Unknown                      | CONFIRMATION NO.<br>Unknown   | GROUP<br>Unknown                |

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

|     |  |
|-----|--|
| AR  | Depoortere, I., <i>et al.</i> , "Dose-Dependent Effects of Recombinant Human Interleukin-11 on Contractile Properties in Rabbit 2,4,6-Trinitrobenzene Sulfonic Acid Colitis <sup>1</sup> ," <i>J. Pharmacol. Exp. Ther.</i> , 294(3): 983-990 (2000).  |
| AS  | Million, M., <i>et al.</i> , "Susceptibility of Lewis and Fischer Rats to Stress-induced Worsening of TNB-colitis: Protective Role of Brain CRF," <i>Amer. Phys. Soc.</i> , 276 (4 Pt 1): G1027-G1036 (1999).  |
| AT  | Owens, M. J., <i>et al.</i> , "Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and their Metabolites <sup>1</sup> ," <i>J. Pharmacol. Exp. Ther.</i> , 283(3): 1305-1322 (1997).  |
| AU  | Kozlowski, C.M., <i>et al.</i> , "The 5-HT <sub>3</sub> Receptor Antagonist Alosetron Inhibits the Colorectal Distention Induced Depressor Response and Spinal <i>c-fos</i> Expression in the Anaesthetised Rat," <i>Gut</i> , 46: 474-480 (2000).   |
| AV  | Ito, C., <i>et al.</i> , "Effect of GK-128 [2-[(2-Methylimidazol-1-yl)methyl]- benzo[f]thiochromen-1-one Monohydrochloride Hemihydrate], a Selective 5-Hydroxytryptamine <sub>3</sub> Receptor Antagonist, on Colonic Function in Rats," <i>J. Pharmacol. Exp. Ther.</i> , 280(1): 67-72 (1997). |
| AW  | Eguchi, J., <i>et al.</i> , "Pharmacological Profile of the Novel Antidepressant 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno-[2,3-d]pyrimidine Monohydrate Hydrochloride," <i>Arzneimittelforschung</i> , 47(12): 1337-1347 (1997).  |
| AX  | Venkova, K., <i>et al.</i> , "Peripheral Activity of a New NK <sub>1</sub> Receptor Antagonist TAK-637 in the Gastrointestinal Tract," <i>J. Pharmacol. Exp. Ther.</i> , 300(3): 1046-1052 (2002).   |
| AY  | Yuan, S.Y., <i>et al.</i> , "Investigation of the Role of 5-HT <sub>3</sub> and 5-HT <sub>4</sub> Receptors in Ascending and Descending Reflexes to the Circular Muscle of Guinea-pig Small Intestine," <i>Br. J. Pharmacol.</i> , 112(4): 1095-1100 (1994).                                     |
| AZ  | Jin, J.G., <i>et al.</i> , "Propulsion in Guinea Pig Colon Induced by 5-Hydroxytryptamine (HT) Via 5-HT <sub>4</sub> and 5-HT <sub>3</sub> Receptors <sup>1</sup> ," <i>J. Pharmacol. Exp. Ther.</i> , 288(1): 93-97 (1999).   |
| AR2 | Greenbaum, D.S., <i>et al.</i> , "Effects of Desipramine on Irritable Bowel Syndrome Compared with Atropine and Placebo," <i>Digestive Diseases and Sciences</i> , 32(3): 257-266 (1987).  |
| AS2 | Center for Drug Evaluation and Research Application Number: 020623; Pharmacology Reviews; July 5, 1996.  |

|          |                 |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|



PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.  
3506.1000-002APPLICATION NO.  
10/757,364INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

February 11, 2004

(Use several sheets if necessary)

FIRST NAMED INVENTOR  
Steven B. LandauFILING DATE  
January 13, 2004EXAMINER  
UnknownCONFIRMATION NO.  
UnknownGROUP  
Unknown

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

|     |   |
|-----|---|
| AT2 | Eguchi, J., <i>et al.</i> , "The Anxiolytic-Like Effect of MCI-225, A Selective NA Reuptake Inhibitor with 5-HT <sub>3</sub> Receptor Antagonism," <i>Pharm. Biochem. and Behavior</i> , 68:677-683 (2001).   |
| AU2 | Schmulson, M.J., "Brain-Gut Interaction in Irritable Bowel Syndrome: New Findings of a Multicomponent Disease Model," <i>IMAJ</i> , 3:104-110 (2001).   |
| AV2 | Camilleri, M., "Serotonergic Modulation of Visceral Sensation: Lower Gut," <i>Gut</i> 51(1):81-86 (2002).   |
| AW2 | Camilleri, M., "Serotonergic Drugs: Emerging Therapies for Irritable Bowel Syndrome," In <i>Irritable Bowel Syndrome a Clinician's Guide</i> , M. Camilleri and R. C. Spiller, eds., Chapt. 19; pp 1-10 (2002).   |
| AX2 | Wood, J.D., <i>et al.</i> "Fundamentals of Neurogastroenterology," <i>Gut</i> 45(2):II6-II16 (1999).  |
| AY2 | Burns, M.J., "The Pharmacology and Toxicology of Reboxetine," <i>Int. J. Med. Toxicol.</i> 3(4):26 1-8 (2000).  |
| AZ2 | Thompson, W.G., <i>et al.</i> , "Functional Bowel Disorders and Functional Abdominal Pain," <i>Gut</i> 45:II43-II47 (1999).   |
| AR3 | Sheikh, M. Y. and Wright, R.A., "Irritable Bowel Syndrome: Current Concepts and Future Prospects," <i>Hospital Physician</i> , pp. 31-38 (March 1999).  |
| AS3 | Schmulson, M.J., "Brain-Gut Interaction in Irritable Bowel Syndrome: New Findings of a Multicomponent Disease Model," <i>IMAJ</i> 3:104-110 (2001).   |
| AT3 | Gebhart, G.F., "Pathobiology of Visceral Pain: Molecular Mechanisms and Therapeutic Implications IV. Visceral Afferent Contributions to the Pathobiology of Visceral Pain," <i>Am. J. Physiol. Gastrointest. Liver Physiol.</i> 278:G834-G838 (2000).   |
| AU3 | Mertz, H.R., "Irritable Bowel Syndrome," <i>N. Engl. J. Med.</i> 349:2136-2146 (2003).  |
| AV3 | Bymaster, F.P., <i>et al.</i> "Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters <i>In Vitro</i> and <i>In Vivo</i> , Human Serotonin Receptor Subtypes, and Other Neuronal Receptors," <i>Neuropsychopharmacology</i> , 25(6):871-880 (2001). |
| AW3 | Béïque, J.C., <i>et al.</i> , Affinities of Venlafaxine and Various Reuptake Inhibitors for the Serotonin and Norepinephrine Transporters," <i>Eur. J. Pharmacol.</i> , 349(1):129-132 (1998).  |

EXAMINER

DATE CONSIDERED



PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.

APPLICATION NO.

3506.1000-002

10/757,364

FIRST NAMED INVENTOR

FILING DATE

Steven B. Landau

January 13, 2004

EXAMINER

CONFIRMATION NO.

GROUP

Unknown


Unknown

Unknown

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

February 11, 2004

(See several sheets if necessary)



## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

|     |   |
|-----|---|
| AX3 | Wong, E.H.F., <i>et al.</i> , "Reboxetine: A Pharmacologically Potent, Selective, and Specific Norepinephrine Reuptake Inhibitor," <i>Biol. Psychiatry</i> , 47(9): 818-829 (2000).   |
| AY3 | Sach, J.A., <i>et al.</i> , "Irritable Bowel Syndrome," <i>Curr. Treat. Options. Gastroenterol.</i> , 5(4): 267-278 (2002).   |
| AZ3 | Angel, I., <i>et al.</i> "Litoxetine: A Selective 5-HT Uptake Inhibitor with Concomitant 5-HT <sub>3</sub> Receptor Antagonist and Antiemetic Properties," <i>Eur. J. Pharmacol.</i> , 232(2-3):139-145 (1993).   |
| AR4 | Fairweather, D.B., <i>et al.</i> , "The Psychomotor and Cognitive Effects of Litoxetine in Young and Middle Aged Volunteers," <i>Br. J. Clin. Pharmacol.</i> , 40(2):119-125 (1995).  |
| AS4 | Morteau, O., <i>et al.</i> , "Influence of 5-HT <sub>3</sub> Receptor Antagonists in Visceromotor and Nociceptive Responses to Rectal Distension Before and During Experimental Colitis In Rats," <i>Fundam. Clin. Pharmacol.</i> , 8(6):553-562 (1994).  |
| AT4 | Goldberg, P.A., <i>et al.</i> , "Modification of Visceral Sensitivity and Pain in Irritable Bowel Syndrome by 5-HT <sub>3</sub> Antagonism (Ondansetron)," <i>Digestion</i> , 57(6):478-483 (1996).   |
| AU4 | LOTRONEX - Tablets, <i>Product Information</i> , GlaxoSmithKline, Research Triangle Park, NC, pp. 1-13 (2002).  |
| AV4 | "Irritable Bowel Syndrome at a Glance - Nosology, Epidemiology, and Pathophysiology (Monograph I), December 2002 [Retrieved on 2002-12-12]. Retrieved from the Internet <URL: <a href="http://fdhn.org/html/education/gi/ibs_nosology.htm">http://fdhn.org/html/education/gi/ibs_nosology.htm</a> > |
| AW4 | U.S. Provisional Application No. 60/364,531, filed 03-15-2002, entitled "Methods of Treating Visceral Pain Syndromes," by Rao <i>et al.</i> , priority document for WO 03/077897 A1 (Reference AQ2) and U.S. 2003/0203055 A1 (Reference AF4).   |
| AX4 | GB 0304648.9, filed 02-28-2003, entitled "New Therapeutic Use of 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperziny) Thieno[2,3-D] Pyrimidine," priority document for WO 2004/004734 A1 (Reference AL2).  |
| AY4 | GB 0216027.3, filed July 10, 2002, entitled "New Therapeutic Use," priority document for WO 2004/004734 A1 (Reference AL2).   |
| AZ4 | Drossman, D.A., <i>et al.</i> , "Irritable Bowel Syndrome: A Technical Review for Practice Guideline Development," <i>Gastroenterology</i> , 112: 2120-2137 (1997).   |

EXAMINER

DATE CONSIDERED